Company Filing History:
Years Active: 2000
Title: Johannes Petrus Langedijk: Innovator in Antibody Research
Introduction
Johannes Petrus Langedijk is a notable inventor based in the Netherlands. He has made significant contributions to the field of antibody research, particularly in relation to respiratory syncytial virus (RSV). His work focuses on developing isolated antibodies that can neutralize RSV, which is crucial for addressing this viral infection.
Latest Patents
Langedijk's latest patents include innovations such as "Human Antibodies Binding To RSV G Protein." This invention provides isolated antibodies and antigen-binding fragments that bind to the G protein of RSV and are capable of neutralizing the virus. Another significant patent is also titled "Human Antibodies Binding To RSV G Protein," which relates to isolated antibodies that can neutralize both RSV A and B subtypes. These antibodies have potential applications in the diagnosis, prophylaxis, and treatment of RSV infections.
Career Highlights
Langedijk is currently associated with Janssen Vaccines & Prevention B.V., where he continues to advance his research in the field of immunology. His work is pivotal in developing therapeutic solutions for RSV, a virus that poses a significant health risk, especially to infants and the elderly.
Collaborations
Throughout his career, Langedijk has collaborated with esteemed colleagues such as Jehangir Wadia and Robert Anthony Williamson. These collaborations have further enriched his research and contributed to the advancement of antibody therapies.
Conclusion
Johannes Petrus Langedijk is a prominent figure in the field of antibody research, with a focus on developing innovative solutions for RSV. His contributions through patents and collaborations highlight his commitment to improving health outcomes related to viral infections.